Buy Zydus Wellness; target of Rs 2000: ICICI Direct
ICICI Direct is bullish on Zydus Wellness recommended buy rating on the stock with a target price of Rs 2000 in its research report dated February 03, 2023.
Sharekhan is bullish on Zydus Wellness has recommended buy rating on the stock with a target price of Rs 1740 in its research report dated February 02, 2023.
The impact of price hikes to mitigate inflationary pressure would be reflected from the fourth quarter onwards in the consumer wellness segment, which accounted for 10% of total revenues in the third quarter, the company said in an exchange filing.
Stocks to buy or sell today: 6 short-term trading ideas by experts for 11 January 2023
“Options data suggests a shift in the trading range in between 17600 to 18300 zones while an immediate trading range in between 17700 to 18200 zones,” Chandan Taparia, Analyst-Derivatives at Motilal Oswal Financial Services Limited, said.
Nithya Balasubramanian on 2 pharma names to bet on besides Sun & Cipla
“Coming to the complex generics opportunity, Cipla and Lupin are most exposed. We like Cipla more than Lupin because at least in the near term, there are multiple assets waiting to play out. For Cipla this year, we are hoping to see generic Advair, generic Abraxane which is most likely in the price but beyond that, there will be a generic Qvar, there will be a generic Teriparatide and potentially a generic Flovent as well.”
Buy Zydus Wellness; target of Rs 2100: ICICI Direct
ICICI Direct is bullish on Zydus Wellness recommended buy rating on the stock with a target price of Rs 2100 in its research report dated November 11, 2022.
Hot Stocks | Sun TV Network, Zydus Wellness can give up to 11% return in short term, here's why
Zydus Wellness has recently given a triangle pattern breakout near its long term support area on the weekly timeframe. The 200 EMA is at Rs 1,680 and the stock is comfortably sustaining above it, which can be used as a confluence to the bullish view.
Buy Zydus Wellness; target of Rs 2140: Anand Rathi
Anand Rathi is bullish on Zydus Wellness has recommended buy rating on the stock with a target price of Rs 2140 in its research report dated September 23, 2022.
Zydus Lifesciences, Lupin recall products in US market owing to manufacturing issues
Zydus initiated the Class II voluntary recall on July 15 this year. Similarly, Baltimore-based Lupin Pharmaceuticals, Inc, is recalling 7,872 bottles of Rifampin Capsules, a medication used to treat infections caused by bacteria.
Bayer introduces medication for chronic kidney disease
"The major focus of therapy in patients with chronic kidney disease and diabetes is to prevent end-stage renal disease or kidney failure. Despite therapy, these patients often progress to kidney failure.
Vijender Singh was most recently CEO of Metropolis Healthcare and COO of Dr. Lals Pathlabs, where Vijender helped scale both these companies under private equity ownership.
Stocks to buy today: 10 short-term trading ideas by experts for 18 August
Sectorally, buying was seen in realty, utilities, power, consumer discretionary, and consumer durables while selling was visible in healthcare, IT, oil & gas, and energy stocks.
Buy Zydus Wellness; target of Rs 2100: ICICI Direct
ICICI Direct is bullish on Zydus Wellness has recommended buy rating on the stock with a target price of Rs 2100 in its research report dated July 31, 2022.
Sharekhan is bullish on Zydus Wellness has recommended buy rating on the stock with a target price of Rs 2250 in its research report dated July 29, 2022.
Zydus Wellness proactively looking for acquisitions; to enter new overseas markets
"The company is confident to drive growth and increase the market share of its brands through innovation, leveraging distribution channels and expanding the brand portfolio," said Zydus Wellness.
Snacks, stationery sales pick up as kids return to school
Physical reopening of educational institutions has thrown a lifeline to categories such as stationeries and school shoes that were hit hard by Covid-19 and study from home, while impulse categories like packaged snacks and confectionery have got a boost amid an overall slowdown in discretionary spending.
Sharekhan is bullish on Zydus Wellness has recommended buy rating on the stock with a target price of Rs 2250 in its research report dated May 17, 2022.
As rupee falls and input costs rise, companies weigh further price hikes
Executives said they may have to push the next round of price hike as early as this month itself despite the last price hike undertaken in end-March or April with the falling rupee impacting their immediate consignment of goods coming into the country.
Buy Zydus Wellness: target of Rs 2250: ICICI Securities
ICICI Securities is bullish on Zydus Wellness recommended buy rating on the stock with a target price of Rs 2250 in its research report dated April 02, 2022.
Emami 'Dermicool' buyout no game changer but up to 56% upside likely
Emami has historically used an inorganic route to growth including the acquisition of Zandu (2009), Kesh King (2015) and German brand Creme 21 (2019). These brands or businesses have over the years emerged as major brands for the company.
Zydus shot to soon join other vaccines in India's Covid fight
The drug regulator had on August 20 given emergency use authorisation (EUA) to the three-dose Covid-19 vaccine, the first in India that can be given to people 12 years and above.